vaccine – Page 6 – Oral Cancer News

Immokalee health clinic earns national award for vaccination rate

Source: www.naplesnews.com Author: Liz Freeman The public health department in Immokalee set a goal for getting children vaccinated against cancer and brought home a U.S. Centers for Disease Control and Prevention award for its high success rate. The Florida Department of Health in Collier County, specifically the Immokalee location, was named the regional winner of the 2017 HPV Vaccine Award because of its 76.2 percent vaccine series completion rate among 13 to 15 year olds. A point-in-time survey in August found 560 children aged 13 to 15 in Immokalee had been vaccinated against HPV, according to a health department spokeswoman. In the last four years, the Immokalee clinic took on an ambitious campaign in the farmworker community to boost HPV vaccination rates, starting with ensuring that all staff members who have contact with clients are knowledgeable about the virus and the vaccine. The virus is common and can cause certain cancer of the genitals, head and neck. There are about 31,000 new cases of cancer a year caused by the virus, according to the CDC. Controversy is attached to the HPV vaccine by some groups who argue that getting kids vaccinated may promote early sexual interaction with others. State governments that have authority over school vaccination requirements have faced debate over requiring it and over the cost State Surgeon General and DOH Secretary Dr. Celeste Philip said she was proud of the Immokalee clinic and its success rate for the vaccinating young people against the virus. “Their commitment to preventing [...]

Oral Cancer Foundation News Team - A2017-11-07T14:02:01-07:00November, 2017|Oral Cancer News|

Know what’s worse than the risks of getting the HPV vaccine? Getting an HPV-related cancer. Trust me

Source: www.statnews.com Author: Michael D. Becker In an era of $500,000 cancer treatments, you’d expect a vaccine series that costs about $300 and helps prevent several types of cancer to be popular with physicians, insurers, and consumers. It’s not, and, as a result, people are dying. I should know — I’m one of them. The human papillomavirus (HPV) can cause changes in the body that lead to six cancers: cervical, vaginal, and vulvar cancer in women; penile cancer in men; and anal cancer in both women and men. It can also cause oropharyngeal cancer — cancer in the back of the throat, including the base of the tongue and tonsils — in both sexes. In the U.S., approximately 30,000 new cancers attributable to HPV are diagnosed each year. In 2006, the first vaccine became available to protect against HPV infection. I was 38 years old at the time, well above the upper age limit of 26 the Centers for Disease Control and Prevention recommends for getting the vaccine. Ideally it should be given before the teen years, but can be given up to age 26. Uptake of the HPV vaccine in the U.S. is abysmal, with just 49 percent of girls and 37 percent of boys having received the recommended HPV vaccination series. Individuals who oppose the use of vaccines argue that safety concerns should preclude the use of the HPV vaccine. I disagree. The safety and effectiveness of this vaccine to protect against cancer-causing strains of the HPV virus [...]

Oral Cancer Foundation News Team - A2017-11-07T13:53:49-07:00November, 2017|Oral Cancer News|

HPV-related oral cancers have risen significantly in Canada

Source: www.ctvnews.ca Author: Sheryl Ubelacker, The Canadian Press The proportion of oral cancers caused by the human papillomavirus has risen significantly in Canada, say researchers, who suggest the infection is now behind an estimated three-quarters of all such malignancies. In a cross-Canada study, published Monday in the Canadian Medical Association Journal, the researchers found the incidence of HPV-related oropharyngeal cancers increased by about 50 per cent between 2000 and 2012. "It's a snapshot of looking at the disease burden and the time trend to see how the speed of the increase of this disease (is changing)," said co-author Sophie Huang, a research radiation therapist at Princess Margaret Cancer Centre in Toronto. Researchers looked at data from specialized cancer centres in British Columbia, Alberta, Ontario and Nova Scotia to determine rates of HPV-related tumours among 3,643 patients aged 18 years or older who had been diagnosed with squamous cell oropharyngeal cancer between 2000 and 2012. HPV is the most common sexually transmitted infection worldwide. Most people never develop symptoms and the infection resolves on its own within about two years. "In 2000, the proportion of throat cancer caused by HPV was estimated at 47 per cent," said Huang. "But in 2012, the proportion became 74 per cent ... about a 50 per cent increase." Statistics from a Canadian Cancer Society report last fall showed 1,335 Canadians were diagnosed in 2012 with HPV-related oropharyngeal cancer and 372 died from the disease. HPV is the most common sexually transmitted infection worldwide. Most people [...]

Oral Cancer Foundation News Team - A2017-08-14T12:10:46-07:00August, 2017|Oral Cancer News|

No HPV Vaccination for Boys in UK

Source: Peter Russell Date: July 20, 2017 Source: www.medscape.com Health bodies are condemning a decision not to include boys in the human papilloma virus (HPV) vaccination programme as "shameful" and a "missed opportunity". The Joint Committee on Vaccination and Immunisation (JCVI) has concluded that it "did not recommend vaccinating boys at this time as it was considered unlikely to be cost-effective". Girls aged 12 to 13 have routinely been offered the HPV jab since September 2008 as part of the NHS childhood vaccination programme. The JCVI has been considering whether to include boys on the scheme since 2014. Protection Against Some Cancers HPV is the name for a group of viruses that are most commonly passed on through genital contact between straight and same-sex partners. It is a very common infection. Almost every sexually active person will get HPV at some time in their lives. Most people who get HPV never develop symptoms or health problems, but for some it can lead to cancer of the cervix, vulva, vagina, penis, anus, and head and neck, as well as cause genital warts. According to health professionals, the virus has been linked to 1 in 20 cases of cancer in the UK. Campaigners in favour of giving boys the jab argue that HPV does not discriminate between the sexes and that offering the vaccine to boys in school would save lives. 'Few Additional Benefits' The JCVI has decided that a high take-up of the vaccine among girls would provide 'herd protection' to [...]

Charlotte Parker2017-08-01T08:42:02-07:00August, 2017|Oral Cancer News|

Plan not to give HPV vaccine to boys causes concern

Source: http://www.bbc.com/news/health-40658791 Date: July 19th, 2017 A decision not to vaccinate boys against a cancer-causing sexually transmitted infection has attracted fierce criticism. Reported cases of human papilloma virus (HPV) - thought to cause about 80% of cervical cancers - have fallen sharply since girls were given the vaccine. But the Joint Committee on Vaccination and Immunisation (JCVI) found little evidence to justify treating boys too. Critics said vaccinating boys could help reduce the risk still further. Across the UK, all girls aged 12-13 are offered HPV vaccination as part of the NHS childhood vaccination programme. Mary Ramsay, head of immunisation at Public Health England, said: "Evidence from around the world suggests that the risk of HPV infection in males is dramatically reduced by achieving high uptake of the HPV vaccine among girls. "While there are some additional benefits to vaccinating both males and females, the current models indicate that extending the programme to boys in the UK, where the uptake in adolescent girls is consistently high (over 85%), would not represent a good use of NHS resources." This initial recommendation by JCVI will now be subject to a public consultation and a final decision will be made in October. The British Dental Association said it would urge the committee to reconsider the evidence. The chair of the BDA, Mick Armstrong, said: "HPV has emerged as the leading cause of oropharyngeal cancers, so JCVI's unwillingness to expand the vaccination programme to boys is frankly indefensible." Shirley Cramer of the Royal Society [...]

Charlotte Parker2017-07-19T09:44:49-07:00July, 2017|Oral Cancer News|

Personalized cancer vaccines successful in first-stage human trials

Source: http://newatlas.com/cancer-personalized-vaccine-success-trial/50402/ Author: Rich Haridy Date: July 9, 2017 A cancer vaccine is one of the holy grails of modern medical research, but finding a way to stimulate the immune system to specifically target and kill cancer cells has proven to be a difficult task. Now two recent clinical trials that have produced encouraging results in patients with skin cancer are are providing hope for the development of personalized cancer vaccines tailored to individual patient's tumors. Both studies focus on neoantigens, which are mutated molecules found only on the surface of cancer cells. Neoantigens prove to be ideal targets for immunotherapy as they are not present on healthy cells. A vaccine's challenge is to train the body's immune cells, known as T cells, to hunt and kill only those specific tumor cells that hold the target neoantigens. In the first trial, at Boston's Dana-Farber Cancer Institute, samples of tumors were taken from six patients with melanoma. The patients were identified as having a high risk for recurrence after first having their tumors removed by surgery. For each individual patient the researchers identified up to 20 neoantigens specific to a subject's tumor. Computer algorithms were then utilized to help the researchers select which specific neoantigens would best stimulate the body's T cells. Those neoantigens were then synthesized, mixed with an adjuvant to stimulate immune response, and injected into the individual patients. Four out of the six patients in this first trial displayed no recurrence of their cancer 25 months after vaccination. [...]

Charlotte Parker2017-07-10T09:33:39-07:00July, 2017|Oral Cancer News|

Biotech exec facing death urges: Get the vaccine that prevents his cancer

Source: www.philly.com Author: Michael D. Becker Like most people who pen a new book, Michael D. Becker is eager for publicity. But he has an unusual sense of urgency. A former oncology biotech CEO, Becker has neck cancer. He expects his 49th birthday in November to be his last, if he makes it. What also drives him to get his message out, however, is this: Children today can get a vaccine that prevents the kind of oropharyngeal cancer that is killing him. As he collides with his mortality, Becker wants to share his story and raise awareness about the vaccine, which protects against dangerous strains of human papillomavirus, or HPV, the extremely common, sexually transmitted virus that caused his disease. His book, A Walk With Purpose: Memoir of a Bioentrepreneur (available on Amazon.com), was produced and self-published in a creative sprint between December, when his cancer recurred just a year after initial diagnosis and treatment, and April. He also has a blog, My Cancer Journey, and has been conducting media interviews. “I had a lot of motivation to write the book quickly,” he said wryly at his home in Yardley. In the final pages, he urges parents “to talk to their doctor about the HPV vaccine,” which “simply didn’t exist when I was a teenager, or it could have prevented my cancer.” The leading vaccine brand, Gardasil, was hailed as a breakthrough when it was introduced in 2006. It is approved to prevent cervical cancer and less common genital malignancies, [...]

Oral Cancer Foundation News Team - A2017-07-06T09:33:47-07:00July, 2017|Oral Cancer News|

Novel vaccine therapy can generate immune responses in patients with HPV-related head and neck cancer

Source: www.news-medical.net Author: staff A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human papillomavirus (HPV), which is frequently associated with HNSCCa, to trigger the immune response. Researchers will present the results of their pilot study during the 2017 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6073). HNSCCa is a cancer that develops in the mucous membranes of the mouth, and throat. While smoking and tobacco use are known causes, the number of cases related to HPV infection - a sexually transmitted infection that is so common, the Centers for Disease Control says almost all sexually active adults will contract it at some point in their lifetimes - is on the rise. The CDC now estimates 70 percent of all throat cancers in the United States are HPV-related. Sixty percent are caused by the subtype known as HPV 16/18. "This is the subtype we target with this new therapy, and we're the only site in the country to demonstrate immune activation with this DNA based immunotherapeutic vaccine for HPV 16/18 associated head and neck cancer," said the study's lead author Charu Aggarwal, MD, MPH, an assistant professor of Hematology Oncology in the Perelman School of Medicine at the University of Pennsylvania. The vaccine is delivered as an injection of antigens - which leads the immune system to start producing antibodies and [...]

Oral Cancer Foundation News Team - A2017-06-01T13:08:47-07:00June, 2017|Oral Cancer News|

More patients presenting with HPV-associated oral cancers in Lubbock, TX

Source: lubbockonline.com Author: Ellysa Harris Detecting oral cancers in patients in their 50s and 60s has never been uncommon. But local dentists and doctors say finding it in younger patient populations has become a new norm. Oral cancers driven by Human Papillomavirus are now the fastest growing oral and oropharyngeal cancers, according to the Oral Cancer Foundation website. And local health officials say they’ve seen a few more cases than usual. Dr. Joehassin Cordero, FACS, professor, chairman and program director ofTexas Tech’s Health Sciences Center Department of Otolaryngology-Head & Neck Surgery, said less people are smoking and that has contributed to the decrease in the number of cases of oral cancers in the past two decades. “In that same period, we have seen an increase in the HPV oropharyngeal cancer,” he said. “And oropharyngeal cancer — what it means it’s affecting the base of your tongue and tonsils.” Dr. Brian Herring, a Lubbock dentist, chalks the increase up to increased awareness. “I’m assuming probably for years and years and years it has affected the mouth but we didn’t know that,” he said. “As we get better at cellular diagnostics and molecular diagnostics, things like that, we’re finding that there is a large portion of cancers that do have an HPV component.” What’s more alarming, said Dr. Ryan Higley, oral surgeon with West Texas Oral Facial Surgery, is it’s being diagnosed in younger people. Higley said oral cancers are generally diagnosed between the ages of 55 and 65, mostly in women. [...]

Oral Cancer Foundation News Team - A2017-05-28T11:56:52-07:00May, 2017|Oral Cancer News|

First long-term study on HPV claims the vaccine is 100% effective at protecting men from cancer caused by the STI

Source: www.dailymail.co.uk Author: Cheyenne Roundtree The first long-term study conducted into the HPV vaccine confirm it is almost 100 percent effective at protecting men from developing oral cancer. The treatment was approved to the market in 2006 to prevent women from getting cervical cancer but experts haven't been able to fully examine its effect over time. Now, the results are in from a three-year study on the effects - the longest investigation ever on HPV. It confirmed that there was no trace of cancer-linked strains of HPV among men who received the vaccine - whereas two percent of untreated men had a potentially cancerous strain. Another study, also released today, found the jab makes it next to impossible for vaccinated children to develop genital warts from the STI in their late teens and 20s. Despite a multitude of interest and research, these are the first substantial studies to confirm the vaccine's ability to protect people from the STI and diseases that can stem from it. Human papillomavirus (HPV) is the most common sexually-transmitted disease in the US, with approximately 80 million people currently infected. Although most infections disappear on their own, without even displaying symptoms, some strains can lead to genital warts and even cancers, including prostate, throat, head and neck, rectum and cervical cancer. Approximately 28,000 cases of cancer caused by HPV are diagnosed annually - most of which would have preventable with the vaccine, the CDC says. The vaccine was first introduced with the main goal to prevent [...]

Oral Cancer Foundation News Team - A2017-05-22T07:38:53-07:00May, 2017|Oral Cancer News|